JAGLX Rating, Research - Janus Global Life Sciences T

Janus Global Life Sciences T (jaglx)

Last Updated by Anonymous | Update This Page Now

►Summary | Add New Mutual Fund | Feedback

Short Term Rating Stock Ratings Help
placeholder_summary.png

Asset Allocation (% of Port)

US Stocks
Non-US Stocks
Bonds
Cash
Other
%
%
%
%
%

Geographic Allocation (% of Port)

North America
Europe
Asia
South America
Africa
Australia + Pacific Islands
Long Term Rating Stock Ratings Help

HOLD

SWOT Statistics

Strengths + Opportunities = 49

Threats + Weaknesses = 35

When strengths & opportunities substantially exceed threats & weaknesses an investment in the jaglx mutual fund has great long term potential.

Fund Management Team

Fund Description Update

Janus Global Life Sciences T (JAGLX) Description: JAGLX is a mutual fund, which is an investment that owns a basket of assets. The JAGLX mutual fund was provided by Janus and this investment vehicle derives the majority of its value from equity holdings (stocks). Januss mutual fund has a medium management tenure and is in the average fund size classification. JAGLXs minimum initial investment amount is $2500 while the IRA minimum is $1000. JAGLXs expense ratio is roughly 1%. The latest JAGLXs front end load was 0% and the back end load was 0%. The Janus Global Life Sciences T (JAGLX) mutual fund falls under the health category. JAGLX focuses its investments in USA and JAGLX is focused on the health industry or fund sector. The Janus Global Life Sciences T (JAGLX) mutual fund is not a leveraged fund and it does not have inverse fund properties. An investor can find JAGLXs top holdings, fundamental analysis, ratings, and fund risk (volatility) on the left side of the screen. The right side of JAGLXs research report features technical analysis and long term investment potential.

Portfolio Strategy Update

Array


Management Analysis Update

Janus Global Life Sciences T's management team has a long history of working together. This helps ensure consistent future returns. Janus Global Life Sciences T has a consistent strategy that will help it to outperform in the future.


Performance Analysis Update